Plain-English translation of NCT05484908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing an artificial liver support system (ALSS) — a medical device that helps clean the blood — for people with liver cancer who have developed severe liver damage after receiving immune checkpoint inhibitor cancer drugs. Immune checkpoint inhibitors are powerful cancer treatments, but in some patients they can cause serious liver problems. The study compares two types of blood-cleaning approaches to see which one works better and is safest.
Immune checkpoint inhibitors are important drugs for advanced liver cancer, but they cause severe liver damage in about 1 in 7 patients. Right now, doctors don't have a proven treatment for this specific type of liver failure, so this trial is exploring whether the artificial liver support system could be a lifesaving option.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to receive either a newer combination blood-cleaning treatment (double plasma molecular adsorption plus low-dose plasma exchange) or a standard blood-cleaning treatment (plasma exchange), along with standard medical care. You will receive these treatments at the hospital and be monitored closely with blood tests and clinical visits from the start of treatment through 12 weeks to track your recovery and any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Enrollment target
~60 participants
Started
August 2022
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenxiong Xu, Doctor
Third Affiliated Hospital, Sun Yat-Sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.